Patents by Inventor Edward Richard Walker

Edward Richard Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTAGONIST COMPOUNDS
    Publication number: 20230293517
    Abstract: The present invention relates to compounds of formula I shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 21, 2023
    Inventors: Clive McCarthy, Ben Moulton, Edward Richard Walker, Pearl Siobhan McMahon
  • NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE
    Publication number: 20230203029
    Abstract: The present invention relates to compounds of Formula (I) that function as inhibitors of MerTK activity, to processes for the preparation of such compounds, to pharmaceutical compositions comprising them and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which (MerTK) activity is implicated: wherein R1, X1, Ring A, Ring B and Ring C are each as defined herein.
    Type: Application
    Filed: April 1, 2021
    Publication date: June 29, 2023
    Inventors: Edward Richard Walker, Timothy William Gorman, Boris Aillard, Clive McCarthy
  • COMPOUNDS
    Publication number: 20220395512
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 15, 2022
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Compounds
    Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Diazepane Compounds Which Modulate The CB2 Receptor
    Publication number: 20100261708
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Application
    Filed: October 21, 2008
    Publication date: October 14, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Pier Francesco Cirillo, Eugene Richard Hickey, Doris Riether, Lifen Wu, Renee M. Zindel, Patricia Amouzegh, Monika Ermann, Edward Richard Walker